Title: METHOD OF TREATING MALIGNANCY ASSOCIATED HYPERCALCEMIA USING ACTIVE VITAMIN D ANALOGUES

Abstract: Methods utilizing active vitamin D analogs for the treatment of malignancy-associated hypercalcemia. Methods comprise the application of an effective amount of a hypocalcemic vitamin D compound to alleviate hypercalcemia, lower serum parathyroid hormone related protein (PTHrP) levels.
METHOD OF TREATING MALIGNANCY ASSOCIATED HYPERCALCEMIA
USING ACTIVE VITAMIN D ANALOGUES

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application Serial No. 09/596,149 filed February 23, 1998, which is a divisional of U.S. application Serial No. 08/781,910, filed December 30, 1996, now U.S. Patent No. 5,763,429, all of which are incorporated herein by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

Not Applicable

BACKGROUND OF THE INVENTION

This invention relates generally to a method of treating malignancy-associated hypercalcemia (MAH), and in particular, to the use of active forms of vitamin D to reduce hypercalcemia associated with inhibit the hyperproliferative diseases.

Extensive research during the past two decades has established important biologic roles for vitamin D apart from its classic role in bone and mineral metabolism. Specific nuclear receptors for 1α,25-dihydroxyvitamin D₃, the hormonally active form of vitamin D, are present in cells from diverse organs not involved in calcium homeostasis. For example, specific, biologically active vitamin D receptors have been demonstrated in the human prostatic carcinoma cell line, LNCaP, (Miller et al., 52 Cancer Res. (1992) 515-520); Vitamin D receptors have also been described for many other neoplastic cells, e.g., carcinomas of the breast and carcinomas of the colon.

It has been reported that certain vitamin D compounds and analogues are potent inhibitors of malignant cell proliferation and are inducers/stimulators of cell differentiation. For example, U.S. Patent No. 4,391,802 issued to Suda et al. discloses
that 1α-hydroxyvitamin D compounds, specifically 1α,25-dihydroxyvitamin D₃ and 1α-hydroxyvitamin D₂, possess potent antileukemic activity by virtue of inducing the differentiation of malignant cells (specifically leukemia cells) to nonmalignant macrophages (monocytes), and are useful in the treatment of leukemia. Antiproliferative and differentiating actions of 1α,25-dihydroxyvitamin D₃ and other vitamin D₃ analogues have been reported with respect to cancer cell lines. More recently, an association between vitamin D receptor gene polymorphism and cancer risk has been reported, suggesting that vitamin D receptors may have a role in the development, and possible treatment, of cancer.

These previous studies have focused exclusively on vitamin D₃ compounds. Even though these compounds may indeed be highly effective in promoting differentiation in malignant cells in culture, their practical use in differentiation therapy as anticancer agents is severely limited because of their equally high potency as agents affecting calcium metabolism. At the levels required in vivo for effective use as, for example, antileukemic agents, these same compounds can induce markedly elevated and potentially dangerous blood calcium levels by virtue of their inherent calcemic activity. That is, the clinical use of 1α,25-dihydroxyvitamin D₃ and other vitamin D₃ analogues as anticancer agents is precluded, or severely limited, by the risk of hypercalcemia.

Hypercalcemia is frequently associated with malignancy (MAH), and is often a major contributor to morbidity and complicates clinical management of the malignancy. Parathyroid hormone related protein (PTHrP) is closely related to parathyroid hormone (PTH) and binds to the same receptor as PTH as well as other receptors. PTHrP is one of the main causative substances of such hypercalcemia, and is overproduced by malignant cells. 1,25-dihydroxyvitamin D₃ has been found to repress the transcription of the PTHrP gene in cells, however, the 1,25-dihydroxyvitamin D₃ compounds themselves increase serum calcium levels. Therefore a need exists for compounds with greater specific activity and selectivity of action, i.e., vitamin D compounds with antiproliferative and differentiating effects but which have less calcemic activity.
The present invention provides a method of treating malignancy-associated hypercalcemia (MAH) such as that associated with hyperproliferative cell growth and/or abnormal cell differentiation. The method includes use of active vitamin D compounds to treat hypercalcemia and reduce serum parathyroid hormone related protein (PTHrP) levels.

The foregoing, and other advantages of the present invention, are realized in one aspect thereof in a method of treating malignancy-associated hypercalcemia from the hyperproliferative activity of human neoplastic or hyperplastic cells, comprising treating the cells with an effective amount of a hypocalcemic hydroxyvitamin D compound having a hydrocarbon moiety substituted at the C-24 position on the sidechain of the molecule. The treating step includes inhibiting proliferation of, and inducing and enhancing differentiation in such cells.

A hydroxyvitamin D compound in accordance with the present invention is an active vitamin D and is suitably represented by the formula (I) described hereafter. Suitable compounds of formula (I) are 1α,24-dihydroxyvitamin D$_2$, 1α,24-dihydroxyvitamin D$_4$, 1α,25-dihydroxyvitamin D$_3$, 1α,25-dihydroxyvitamin D$_2$, 1α-hydroxyvitamin D$_2$ and 1α-hydroxyvitamin D$_4$.

The effective or therapeutic amount of the hypocalcemic hydroxyvitamin D compounds administrable in accordance with the present invention to patients in need on a daily basis per kilogram of body weight ranges from 0.01 μg/kg/day to 2.0 μg/kg/day.

In another aspect of the invention, lowering serum parathyroid hormone related protein (PTHrP) levels in patients suffering from hypercalcemia is accomplished by a method comprising, administering to these patients an effective amount of a hypocalcemic vitamin D compound, to lower the serum parathyroid hormone related protein (PTHrP) level.

The hypocalcemic vitamin D compounds are also valuable for the treatment of breast, prostate and colon cancer, as well as other neoplasms such as pancreatic cancer, endometrial cancer, testicular cancer, small cell and non-small cell cancer of the lung.
(including squamous, adenocarcinoma and large cell types), squamous cell of the head and neck, bladder, ovarian and cervical cancers, myeloid and lymphocytic leukemia, lymphoma, hepatic tumors, medullary thyroid carcinoma, multiple myeloma, retinoblastoma, and sarcomas of the soft tissue and bone, i.e. neoplasms that express a vitamin D receptor.

In accordance with the present invention, when effective amounts of the hypocalcemic vitamin D compounds are administered to patients with MAH, significantly reduced hypercalcemia is observed than is observed after the same amount of an activated vitamin D$_3$ (e.g., 1α-OH D$_3$, 1α,25-(OH)$_2$ D$_3$) is administered in previously known formulations. Thus, the compound in accordance with the present invention has an improved therapeutic index relative to active forms of vitamin D$_3$ analogues.

Accordingly, another aspect of the invention is a method of treating malignancy associated hypercalcemia comprising administering to a subject who is suffering therefrom an effective amount of active vitamin D compound which has, or attains through metabolism in vivo, a vitamin D receptor (VDR) binding affinity substantially equivalent to the binding affinity of 1α,25-dihydroxyvitamin D$_3$ and has a hypercalcemia risk substantially lower that of 1α,25-dihydroxyvitamin D$_3$, to normalize or reduce serum calcium levels.

For treatment for malignancy-associated hypercalcemia and the underlying malignant condition in accordance with the present invention, the active vitamin D is suitably administered alone as an active ingredient in a pharmaceutical composition, or is co-administered with an anticancer agent.

Further, included within the scope of the present invention is the co-administration of a hypocalcemic vitamin D compound with a cytotoxic or anticancer agent. Such agents suitably include antimetabolites (e.g., 5-fluoro-uracil, methotrexate, fludarabine), antimicrotubule agents (e.g., vincristine, vinblastine, taxanes such as paclitaxel, docetaxel), an alkylating agent (e.g., cyclophosphamide, melphalan,
biochloroethylnitrosurea, hydroxyurea), platinum agents (e.g. cisplatin, carboplatin, oxaliplatin, JM-216, CI-973), anthracyclines (e.g., doxorubicin, daunorubicin), antibiollitics (e.g., mitomycin, idarubicin, adriamycin, daunomycin), topoisomerase inhibitors (e.g., etoposide, camptothecins) or any other antineoplastic agents.

It is anticipated that the active vitamin D compounds used in combination with various anticancer drugs can give rise to a significantly enhanced cytotoxic effect on cancerous cells, thus providing an increased therapeutic effect. Specifically, as a significantly increased growth-inhibitory effect is obtained with the above disclosed combinations utilizing lower concentrations of the anticancer drugs compared to the treatment regimes in which the drugs are used alone, there is the potential to provide therapy wherein adverse side effects associated with the anticancer drugs are considerably reduced than normally observed with the anticancer drugs used alone in larger doses. Possible dose ranges of these co-administered anticancer agents are about 0.1 to 20 mg/kg/day.

Also included within the scope of the present invention is the co-administration of effective dosages of a hypocalcemic vitamin D compound in conjunction with administration of hormones or other agents, e.g., estrogens, which are known to ameliorate bone diseases or disorders. For example, prostate cancer often metastasizes to bone, causing bone loss and associated pain. Such bone agents may include conjugated estrogens or their equivalents, calcitonin, bisphosphonates, calcium supplements, cobalamin, pertussis toxin and boron.

In another aspect, the invention is a pharmaceutical composition which includes an anticancer agent which is an active hypocalcemic vitamin D compound; an agent selected from the group consisting of (i) an anticancer agent, (ii) a bone agent, and combinations thereof; and a physiologically acceptable carrier.

Other advantages and a fuller appreciation of specific adaptations, compositional variations, and physical attributes will be gained upon an examination of the following
detailed description of preferred embodiments, taken in conjunction with the appended claims.

BRIEF DESCRIPTION OF THE DRAWING(S)

Not Applicable

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides an effective method for the treatment of hypercalcemia, i.e. unphysiologically high and deleterious blood calcium levels, associated with neoplastic and hyperproliferative diseases. Particularly, the present invention relates to therapeutic methods for ameliorating or alleviating the hypercalcemia associated with the hyperproliferative cellular activity of malignant and neoplastic diseases, as well as inducing, enhancing or promoting cell differentiation in the diseased cells. The present invention provides a novel treatment of a patient suffering from a hyperproliferative disease with an active hypocalcemic vitamin D compound. Preferably, the active vitamin D analogue is a hydroxyvitamin D compound and is suitably represented by formula (I) as described hereinbelow. The active vitamin D analogue is provided to the patient without itself causing dose-limiting hypercalcemia and hypercalciuria, and in fact, reduces the hypercalcemia caused by the malignancy. These attributes are achieved through specific chemical properties of the hypocalcemic vitamin D compounds as described.

In accordance with the present invention, when effective amounts of the hypocalcemic active vitamin D compounds are administered to patients with malignant diseases, the hypercalcemia is reduced, the PTHrP serum level is reduced, and the proliferative activity of the abnormal cells is inhibited, reduced, or stabilized, and cell differentiation is induced, promoted or enhanced. Thus, the hypocalcemic vitamin D compounds of the present invention have an improved therapeutic index relative to active forms of vitamin D$_3$ analogues.
It is known that vitamin D₃ must be hydroxylated in the C-1 and C-25 positions before it is activated, i.e., before it will produce a biological response. A similar metabolism appears to be required to activate other forms of vitamin D, e.g., vitamin D₂ and vitamin D₄. Therefore, as used herein, the term "activated vitamin D" or "active vitamin D" is intended to refer to a vitamin D compound or analogue that has been hydroxylated in at least the C-1, C-24 or C-25 position of the molecule and either the compound itself or its metabolites in the case of a prodrug, such as 1α-hydroxyvitamin D₂, binds the vitamin D receptor (VDR). For example, "prodrugs" are vitamin D compounds which are hydroxylated in the C-1. Such compounds undergo further hydroxylation in vivo and their metabolites bind the VDR.

The term “hypocalcemic vitamin D compound” is in reference to active vitamin D analogs which demonstrate hypocalcemic activity, i.e., have low calcemic activity relative to that of 1α,25-dihydroxyvitamin D₃, including 24-hydroxyvitamin D compounds, 25-hydroxyvitamin compounds and 1α-hydroxyvitamin compounds.

Also, as used herein, the term "lower" as a modifier for alkyl, alkenyl acyl, or cycloalkyl is meant to refer to a straight or branched, saturated or unsaturated hydrocarbon radical having 1 to 4 carbon atoms. Specific examples of such hydrocarbon radicals are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, ethenyl, propenyl, butenyl, isobutenyl, isopropenyl, formyl, acetyl, propionyl, butyryl or cyclopropyl. The term "aromatic acyl" is meant to refer to a unsubstituted or substituted benzoyl group.

As used herein, the term "hydrocarbon moiety" refers to a lower alkyl, a lower alkenyl, a lower acyl group or a lower cycloalkyl, i.e., a straight or branched, saturated or unsaturated C₁-C₄ hydrocarbon radical.

The compound in accordance with the present invention is an active hypocalcemic vitamin D compound. The active vitamin D provided is such that the compound has a hydrocarbon moiety at the C-24 position, e.g. a lower alkyl, alkenyl or acyl group as the C-24 position. Further, the active vitamin D in accordance with the present invention may have an unsaturated sidechain, e.g., there is suitably a double bond between C-22 and C-23, between C-25 and C-26 or between C-26 and C-27.
The hypocalcemic hydroxyvitamin D of the present invention suitably has the general formula described in formula (I)

\[
\text{(I)}
\]

wherein \(A^1\) and \(A^2\) each are hydrogen or a carbon-carbon bond, thus forming a double bond between C-22 and C-23; \(R^1\) and \(R^2\) are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that \(R^1\) and \(R^2\) cannot both be alkenyl, or taken together with the carbon to which they are bonded, form a \(C_3-C_8\) cyclocarbon ring; \(R^3\) is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; \(X^1\) is hydrogen or hydroxyl, \(X^2\) is hydrogen or hydroxyl, or, may be taken with \(R^1\) or \(R^2\), to constitute a double bond, and \(X^3\) is hydrogen or hydroxyl provided that at least one of \(X^1, X^2\), or \(X^3\) is hydroxyl, and \(Y\) is a methylene group if the bond to \(Y\) is a double bond or is a methyl group or hydrogen if the bond to \(Y\) is a single bond.
A 1α-hydroxyvitamin D compound of formula (I) is characterized by the general formula (II):

wherein \( A^1 \) and \( A^2 \) each are hydrogen or a carbon-carbon bond, thus forming a double bond between C-22 and C-23; \( R^1 \) and \( R^2 \) are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that \( R^1 \) and \( R^2 \) cannot both be an alkenyl, or taken together with the carbon to which they are bonded, form a C₃-C₈ cyclocarbon ring; \( R^3 \) is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; \( X^1 \) is hydrogen or hydroxyl, \( X^2 \) is hydrogen or hydroxyl, or, may be taken with \( R^1 \) or \( R^2 \), to constitute a double bond, and \( Y \) is a methylene group if the bond to \( Y \) is a double bond or is a methyl group or hydrogen if the bond to \( Y \) is a single bond.
Specifically, 1α-hydroxyvitamin D compounds in accordance with the present invention are characterized by the general formula (III):

![Chemical Structure](image)

wherein \( A^1 \) and \( A^2 \) each are hydrogen or a carbon-carbon bond, thus forming a double bond between C-22 and C-23; \( R^1 \) and \( R^2 \) are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that \( R^1 \) and \( R^2 \) cannot both be an alkenyl, or taken together with the carbon to which they are bonded, form a C\(_3\)-C\(_8\) cyclocarbon ring; \( R^3 \) is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; \( X^1 \) is hydrogen or hydroxyl, and \( X^2 \) is hydrogen or hydroxyl, or, may be taken with \( R^1 \) or \( R^2 \), to constitute a double bond.

The hypocalcemic hydroxyvitamin D compounds of the present invention are those that have effective antiproliferative and cell differentiation activity (i.e., reversal of malignant transformation), but have a lower tendency or inability to cause hypercalcemia and/or hypercalciuria i.e. they are hypocalcemic compounds that have low calcemic activity relative to that of 1α,25-dihydroxyvitamin D\(_3\). In other words, the compounds of the present invention can be administered at dosages that allow them to act as antiproliferative agents and cell differentiation agents when exposed to malignant or other hyperproliferative cells and can reduce hypercalcemia associated with the
malignancy. This selectivity and specificity of action makes the hypocalcemic vitamin D compounds useful and preferred antihypercalcemic agents as well as safely inhibiting hyperproliferation and promoting malignant or hyperplastic cell differentiation. The compounds of the present invention, thus, overcome the shortcomings of the known active vitamin D₃ compounds described above, and can be considered preferred agents for the control and treatment of malignant diseases such breast, prostate, testicular and colon cancer, as well as other neoplasms such as pancreatic cancer, endometrial cancer, small cell and non-small cell cancer of the lung (including squamous, adenocarcinoma and large cell types), squamous cell of the head and neck, bladder, ovarian and cervical cancers, myeloid and lymphocytic leukemia, lymphoma, hepatic tumors, medullary thyroid carcinoma, multiple myeloma, melanoma retinoblastoma, and sarcomas of the soft tissue and bone, i.e. neoplasms that express vitamin D receptors.

Suitable hypocalcemic vitamin D compounds in accordance with the present invention include: 1α,24-dihydroxyvitamin D₂, 1α,24-dihydroxyvitamin D₄, 1α,25-dihydroxyvitamin D₂, 1α,25-dihydroxyvitamin D₄, 1α-hydroxyvitamin D₂, and 1α-hydroxyvitamin D₄. Among those compounds of formula (I) that have a chiral center in the sidechain, such as at C-24, it is understood that both epimers (e.g., R and S) and the racemic mixture are within the scope of the present invention.

Thus, the present invention provides a method of treating hypercalcemia associated with malignant cells with an effective amount of a hypocalcemic vitamin D compound. The effective dosage amount on a daily basis per kilogram of body weight of the patient ranges from about 0.01 μg/kg/day to about 2.0 μg/kg/day.

The compounds of formula (I) can be prepared as described, e.g., in U.S. Patent 5,488,120 issued to Knutson et al., U.S. Patent 4,670,190 and 4,554,106 issued to DeLuca et al., U.S. Patent 5,486,636 issued to DeLuca et al., and Strugnell et al., 310 Biochem. J. (1995) pp. 233-241, all of which are incorporated herein by reference.

The biopotencies of the compounds of formula (I) have been studied and compared to that of 1α,25-dihydroxyvitamin D₃, the active hormonal form of vitamin D and the standard against which all vitamin D compounds and analogues are measured. For example, it has been found that the vitamin D receptor (VDR) binding affinities of
the compounds of formula (I), or their active metabolites, are substantially equivalent to (i.e., equal to or up to 3 times weaker than) the affinity of 1α,25-dihydroxyvitamin D₃. Such receptor binding affinities are indicative of potent biological activity.

At the same time, it has been found that compounds of formula (I) are significantly less toxic than their corresponding vitamin D₃ analogues. For example, in parent co-pending application, Ser. No. 08/265,438, the disclosure of which is incorporated herein by reference, the LD₅₀ for 1α-hydroxyvitamin D₄ was found to be 1.0 mg/kg in males and 3.0 mg/kg in females, i.e., substantially less toxic than 1α-hydroxyvitamin D₃ (LD₅₀ ~ 0.2 mg/kg). Further, in the parent U.S. Patent No. 5,403,831, and its grandparent U.S. Patent 5,104,864, both of which are incorporated herein by reference, it has been shown that 1α-hydroxyvitamin D₂ has the same biopotency as 1α-hydroxyvitamin D₃ and 1α,25-dihydroxyvitamin D₃ but is much less toxic. Even dosages up to 10 µg/day of 1α-hydroxyvitamin D₂ in women with postmenopausal osteoporosis elicited only mild hypercalciuria (U.Ca >300 mg/24 hrs), and no marked hypercalcemia (S. Ca>11.0 mg/dL) solely due to 1α-hydroxyvitamin D₂ was evident. Additionally, the compound did not adversely affect kidney function, as determined by creatinine clearance and BUN; nor did it increase urinary excretion of hydroxyproline, indicating the absence of any stimulatory effect on bone resorption. Administration of 1α-hydroxyvitamin D₂ to healthy adult males in dosages up to 8 µg/day showed no clinically significant hypercalcemia or other adverse effects.

The hypocalcemic vitamin D compounds of the present invention are useful as active compounds in pharmaceutical compositions having reduced side effects and low toxicity as compared with the known analogues of active forms of vitamin D₃.

The pharmacologically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, e.g., mammals including humans. For example, the hypocalcemic vitamin D compounds can be employed in admixtures with conventional excipients, e.g., pharmaceutically acceptable carrier substances suitable for enteral (e.g., oral), parenteral or topical application which do not deleteriously react with the active compounds.
Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils (e.g., almond oil, corn oil, cottonseed oil, peanut oil, olive oil, coconut oil), mineral oil, fish liver oils, oily esters such as Polysorbate 80, polyethylene glycols, gelatine, carbohydrates (e.g., lactose, amylose or starch), magnesium stearate, talc, silicic acid, viscous paraffin, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxy methylcellulose, polyvinyl pyrrolidone, etc.

The pharmaceutical preparations can be sterilized and, if desired, be mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring, flavoring and/or one or more other active compounds, for example, vitamin D₃ and its 1α-hydroxylated metabolites, conjugated estrogens or their equivalents, anti-estrogens, calcitonin, biphosphonates, calcium supplements, cobalamin, pertussis toxin and boron.

For parenteral application, particularly suitable are injectable, sterile solutions, preferably oily or aqueous solution, as well as suspensions, emulsions, or implants, including suppositories. Parenteral administration suitably includes subcutaneous, intramuscular, or intravenous injection, nasopharyngeal or mucosal absorption, or transdermal absorption. Ampoules are convenient unit dosages.

For enteral application, particularly suitable are tablets, dragees, liquids, drops, suppositories, lozenges, powders, or capsules. A syrup, elixir, or the like can be used if a sweetened vehicle is desired.

For topical application, suitable nonsprayable viscous, semi-solid or solid forms can be employed which include a carrier compatible with topical application and having a dynamic viscosity preferably greater than water, for example, mineral oil, almond oil, self-emulsifying beeswax, vegetable oil, white soft paraffin, and propylene glycol. Suitable formulations include, but are not limited to, creams, ointments, lotions, solutions, suspensions, emulsions, powders, liniments, salves, aerosols, transdermal patches, etc., which are, if desired, sterilized or mixed with auxiliary agents, e.g.,
preservatives, stabilizers, demulsifiers, wetting agents, etc. A cream preparation in
accordance with the present invention suitably includes, for example, mixture of water,
almond oil, mineral oil and self-emulsifying beeswax; an ointment preparation suitably
includes, for example, almond oil and white soft paraffin; and a lotion preparation
suitably includes, for example, dry propylene glycol.

Topical preparations of the compound in accordance with the present invention
useful for the treatment of skin disorders may also include epithelialization-inducing
agents such as retinoids (e.g., vitamin A), chromanols such as vitamin E, β-agonists such
as isoproterenol or cyclic adenosine monophosphate (cAMP), anti-inflammatory agents
such as corticosteroids (e.g., hydrocortisone or its acetate, or dexamethasone) and
keratoplastic agents such as coal tar or anthralin. Effective amounts of such agents are,
for example, vitamin A about 0.003 to about 0.3% by weight of the composition;
vitamin E about 0.1 to about 10%; isoproterenol about 0.1 to about 2%; cAMP about 0.1
to about 1%; hydrocortisone about 0.25 to about 5%; coal tar about 0.1 to about 20%;
and anthralin about 0.05 to about 2%.

For rectal administration, the compound is formed into a pharmaceutical
composition containing a suppository base such as cacao oil or other triglycerides. To
prolong storage life, the composition advantageously includes an antioxidant such as
ascorbic acid, butylated hydroxyanisole or hydroquinone.

For treatment of hypercalcemia associated with malignancy, oral administration of
the pharmaceutical compositions of the present invention is preferred. Generally, the
compound of this invention is dispensed by unit dosage form comprising about 0.5 µg to
about 25 µg in a pharmaceutically acceptable carrier per unit dosage. The dosage of the
compound according to this invention generally is about 10 µg to 200 µg/day.

For topical treatment of skin disorders, the dosage of the compound of the
present invention in a topical composition generally is about 0.01 µg to about 50 µg per
gram of composition. For treatment of skin cancers, the dosage of the hypocalcemic
vitamin D compound in a locally applied composition generally is about 0.01 μg to 100 μg per gram composition.

It is noted that dosing of the hypocalcemic compounds in accordance with the present invention can also be done on an episodic basis, in which case higher doses can be used generally about 20μg to about 200 μg given once every 2 to 7 days. The dose can be given as a single dose or a divided dose in 2 to 5 subdoses, the subdoses given, e.g., one every hour until the total dose is taken.

Those of ordinary skill in the art will readily optimize effective doses and coadministration regimens as determined by good medical practice and the clinical condition of the individual patient. Regardless of the manner of administration, it will be appreciated that the actual preferred amounts of active compound in a specific case will vary according to the efficacy of the specific compound employed, the particular compositions formulated, the mode of application, and the particular situs and organism being treated. For example, the specific dose for a particular patient depends on age, body weight, general state of health, on diet, on the timing and mode of administration, on the rate of excretion, and on medications used in combination and the severity of the particular disorder to which the therapy is applied. Dosages for a given host can be determined using conventional considerations, e.g., by customary comparison of the differential activities of the subject compounds and of a known agent, such as by means of an appropriate conventional pharmacological protocol.

Further, included within the scope of the present invention is the co-administration of a hypocalcemic vitamin D compound with a anticancer agent, e.g., a cytotoxic agent. Such agents suitably include antimetabolites (e.g., 5-fluoro-uracil, methotrexate, fludarabine), antimicrotubule agents (e.g., vincristine, vinblastine, taxanes such as paclitaxel, docetaxel), an alkylating agent (e.g., cyclophosphamide, melphalan, biochboroethylnitrosurea, hydroxyurea), platinum agents (e.g. cisplatin, carboplatin, oxaliplatin, JM-216, CI-973), anthracyclines (e.g., doxorubicin, daunorubicin), antibioliics (e.g., mitomycin, idarubicin, adriamycin, daunomycin), topoisomerase inhibitors (e.g., etoposide, camptothecins) or any other antineoplastic agents.
(estramustine phosphate, prednimustine). It is anticipated that the hypocalcemic vitamin D compounds used in combination with various anticancer drugs can give rise to a significantly enhanced cytotoxic effect on cancerous cells, thus providing an increased therapeutic effect. Specifically, as a significantly increased growth-inhibitory effect is obtained with the above disclosed combinations utilizing lower concentrations of the anticancer drugs compared to the treatment regimes in which the drugs are used alone, there is the potential to provide therapy wherein adverse side effects associated with the anticancer drugs are considerably reduced than normally observed with the anticancer drugs used alone in larger doses. Possible dose ranges of these co-administered anticancer agents are about 0.1 to 20 mg/kg/day.

The term “co-administration” is meant to refer to any administration route in which two or more agents are administered to a patient or subject. For example, the agents may be administered together, or before or after each other. The agents may be administered by different routes, e.g., one agent may be administered intravenously while the second agent is administered intramuscularly, intravenously or orally. The agents may be administered simultaneously or sequentially, as long as they are given in a manner sufficient to allow both agents to achieve effective concentrations in the body. The agents also may be in an admixture, as, for example, in a single tablet. In sequential administration, one agent may directly follow administration of the other or the agents may be give episodically, i.e., one can be given at one time and the other at a later time, typically within a week. An example of a suitable co-administration regimen is where a hypocalcemic vitamin D compound is administered from 0.5 to 7 days prior to administration of a cytotoxic agent.

Also included within the scope of the present invention is the co-administration of effective dosages of the analogue of formula (I) in conjunction with administration of hormones or other agents, e.g., estrogens, which are known to ameliorate bone diseases or disorders. As noted above, prostate cancer often metastasizes to bone, causing bone loss and associated pain. Such bone agents may include conjugated estrogens or their equivalents, calcitomin, bisphosphonates, calcium supplements, cobalamin, pertussis toxin and boron. It is contemplated that these bone agents also have an antihypercalcemic effect and may enhance the treatment of malignancy-associated
hypercaldemia. Possible dose ranges for these co-administered bone agents are provided in Table 1.

**TABLE 1**

<table>
<thead>
<tr>
<th>Agent</th>
<th>Dose Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conjugated Estrogens or Equivalent (mg/day)</td>
<td>0.3-5.0 0.4-2.4 0.6-1.2</td>
</tr>
<tr>
<td>Sodium Fluoride (mg/day)</td>
<td>5-150 30-75 40-60</td>
</tr>
<tr>
<td>Calcitonin (IU/day)</td>
<td>5-800 25-500 50-200</td>
</tr>
<tr>
<td>Bisphosphonates (mg/day)</td>
<td>0.5-20 1-15 5-10</td>
</tr>
<tr>
<td>Calcium Supplements (mg/day)</td>
<td>250-2500 500-1500 750-1000</td>
</tr>
<tr>
<td>Cobalamin (µg/day)</td>
<td>5-200 20-100 30-50</td>
</tr>
<tr>
<td>Pertussis Toxin (mg/day)</td>
<td>0.1-2000 10-1500 100-1000</td>
</tr>
<tr>
<td>Boron (mg/day)</td>
<td>0.10-3000 1-250 2-100</td>
</tr>
</tbody>
</table>

Antiestrogens, such as Tamoxifen™, are also known bone agents and may be suitably used in conjunction with the hypocalcemic hydroxyvitamin D compounds of the present invention.

The present invention is further explained by the following examples which should not be construed by way of limiting the scope of the present invention.
VDR BINDING ANALYSES

Example 1: 1α,24-dihydroxyvitamin D$_2$ [1α,24-(OH)$_2$D$_2$]

The affinity of 1α,24-(OH)$_2$D$_2$ for the mammalian vitamin D receptor (VDR) was assessed using a commercially available kit of bovine thymus VDR and standard 1,25-(OH)$_2$D$_3$ solutions from Incstar (Stillwater, Minnesota). The half-maximal binding of chemically synthesized 1α,24-(OH)$_2$D$_2$ was approximately 150 pg/ml whereas that of 1α,25-(OH)$_2$D$_3$ was 80 pg/ml. Thus, the 1α,24-(OH)$_2$D$_2$ had a very similar affinity for bovine thymus VDR as did 1α,25-(OH)$_2$D$_3$, indicating that 1α,24-(OH)$_2$D$_2$ has potent biological activity.

Example 2: 1α,24-dihydroxy vitamin D$_4$ [1α,24-(OH)$_2$D$_4$]

The VDR affinity binding of 1α,24-(OH)$_2$D$_4$ was investigated. The 1α,24-(OH)$_2$D$_4$ was incubated with vitamin D receptor and radiolabeled tracer 1α,25-(OH)$_2$D$_3$. After incubation, the amount of radioactivity bound to the receptor was determined and compared with the amount bound after co-incubation of unlabeled and labeled 1α,25-(OH)$_2$D$_3$. It was found that 50 pg/tube of 1α,24-(OH)$_2$D$_4$ was equivalent to approximately 20 pg 1α,25-(OH)$_2$D$_3$.

These results show that 1α,24-(OH)$_2$D$_4$ binds slightly less tightly to the vitamin D receptor than does 1α,25-(OH)$_2$D$_3$. Such data mean that 1α,24-(OH)$_2$D$_4$ has high affinity for the VDR and significant biological activity, similar to that of 1α,25-(OH)$_2$D$_3$. These data are consistent with gene expression studies done (described below) with 1α,24-(OH)$_2$D$_4$ which demonstrate that 1α,24-(OH)$_2$D$_4$ is only slightly less active than is 1α,25-(OH)$_2$D$_3$.

These results are surprising and unexpected in view of the prior art. They are contrary to the normative wisdom in the vitamin D art regarding the very low degree of biological activity of vitamin D$_4$ compounds.

Example 3: 1α,24-dihydroxyvitamin D$_2$ [1α,24-(OH)$_2$D$_2$]

VDR binding of vitamin D compounds by prostate cells is demonstrated using the techniques of Skowronsksi et al., 136 Endocrinology (1995) 20-26, which is incorporated herein by reference. Prostate-derived cell lines are cultured to near
confluence, washed and harvested by scraping. Cells are washed by centrifugation, and
the cell pellet resuspended in a buffered salt solution containing protease inhibitors. The
cells are disrupted by sonication while cooling on ice. The supernatant obtained from
centrifuging the disrupted cells at 207,000 x g for 35 min at 4EC is assayed for binding.

200 TL of soluble extract, (1-2 mg protein/ml supernatant) is incubated with a 1 nM
$^3$H-1α,25-(OH)$_2$D$_3$ and increasing concentrations of 1α,24-(OH)$_2$-D$_2$ (0.01-100 nM) for
16-20 hr at 4EC. Bound and free hormones are separated with hydroxylapatite using
standard procedures. Specific binding is calculated by subtracting nonspecific binding
obtained in the presence of a 250-fold excess of nonradioactive 1α,25-(OH)$_2$D$_3$ from the
total binding measured. The results demonstrate that 1α,24-(OH)$_2$D$_2$ has strong affinity
for prostate VDR, indicating that 1α,24-(OH)$_2$D$_2$ has potent biological activity in respect
of prostate cells.

Example 4: 1α,24-dihydroxy vitamin D$_4$ [1α,24-(OH)$_2$D$_4$]

The procedure of Example 3 is repeated using the active vitamin D analogue
1α,24-(OH)$_2$D$_4$, and the specific binding is determined. The results demonstrate that
1α,24-(OH)$_2$D$_4$ has strong affinity for prostate VDR, indicating that 1α,24-(OH)$_2$D$_4$ has
potent biological activity in respect of prostate cells.

Example 5: 1α,25-dihydroxyvitamin D$_4$ [1α,25-(OH)$_2$D$_4$]

The procedure of Example 3 is repeated using the active vitamin D analogue
1α,25-(OH)$_2$D$_4$, and the specific binding is determined. The results demonstrate that
1α,25-(OH)$_2$D$_4$ has strong affinity for prostate VDR, indicating that 1α,25-(OH)$_2$D$_4$ has
potent biological activity in respect of prostate cells.

GENE EXPRESSION

Example 6: 1α,24-dihydroxy vitamin D$_4$ [1α,24-(OH)$_2$D$_4$]

Using the plasmids p(CT4)$^+TKGH$, a vitamin D receptor (VDR)-expressing plasmid, and pSG5-hVDR1/3, a plasmid containing a Growth Hormone (GH) gene,
under the control of a vitamin D-responsive element (VDRE), experiments were
conducted to explore the ability of 1α,24-(OH)$_2$D$_4$ to induce vitamin D-dependent
growth hormone acting as a reporter gene compared to that of 1α,25-(OH)$_2$D$_3$. Cells in
culture were transfected with these two plasmids. One plasmid contained the gene for Growth Hormone (GH) under the control of the vitamin D responsive element (VDRE) and the other plasmid contained the structural gene for the vitamin D receptor (VDR). These transfected cultures were incubated with 1α,24-(OH)₂D₄ or 1α,25-(OH)₂D₃, and the production of growth hormone was measured. Table 2 below shows the results of this assay:

**TABLE 2**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Concentration Used (M)</th>
<th>Growth Hormone Induction (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,25-(OH)₂D₃</td>
<td>1 x 10⁻¹⁰</td>
<td>39</td>
</tr>
<tr>
<td>1,25-(OH)₂D₃</td>
<td>5 x 10⁻¹⁰</td>
<td>248</td>
</tr>
<tr>
<td>1,24-(OH)₂D₄</td>
<td>5 x 10⁻¹⁰</td>
<td>165</td>
</tr>
<tr>
<td>1,24-(OH)₂D₄</td>
<td>1 x 10⁻⁹</td>
<td>628</td>
</tr>
<tr>
<td>1,24-(OH)₂D₄</td>
<td>5 x 10⁻⁹</td>
<td>1098</td>
</tr>
</tbody>
</table>

These data show that the ability of 1α,24-(OH)₂D₄ to stimulate vitamin D-dependent growth hormone is nearly equivalent to that of 1α,25-(OH)₂D₃. Such results are truly surprising and would not have been expected by following the teachings of the prior art.

**Example 7:** 1α,24(S)-dihydroxyvitamin D₂ and 1α,24(R)-dihydroxy-vitamin D₂

[1α,24(S)-(OH)₂D₂ and 1α,24(R)-(OH)₂D₂]

The gene expression study described in Example 6 was conducted to compare the biological activity *in vitro* of chemically synthesized 1α,24(S)-(OH)₂D₂ and 1α,24(R)-(OH)₂D₂, with 1α,25-(OH)₂D₃ and 25-OH-D₃. The vitamin D-dependent transcriptional activation model system was used in which plasmids pSG5-hVDR1/3 and p(CT₄)₄TKGH were co-transfected into Green monkey kidney, COS-1 cells.

Transfected cells were incubated with vitamin D metabolites and growth hormone production was measured. As shown in Table 3, both 1α,24(S)-(OH)₂D₂ and
its epimer, 1α,24(R)-(OH)2D2, had significantly more activity in this system than 25-OH-D3, with 1α,24(S)-(OH)2D2 having nearly the same activity as 1α,25-(OH)2D3.

### TABLE 3

Vitamin D Inducible Growth Hormone Production

In Transfected COS-1 Cells

<table>
<thead>
<tr>
<th>Inducer</th>
<th>Molar Concentration</th>
<th>Total GH Production* (ng/ml)</th>
<th>Net vitamin DCinducible GH-production (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethanol</td>
<td></td>
<td>44</td>
<td>0</td>
</tr>
<tr>
<td>25-OH-D3</td>
<td>1x10^-7</td>
<td>245</td>
<td>201</td>
</tr>
<tr>
<td></td>
<td>1x10^-6</td>
<td>1100</td>
<td>1056</td>
</tr>
<tr>
<td></td>
<td>1x10^-5</td>
<td>775</td>
<td>731</td>
</tr>
<tr>
<td>1α,25-(OH)2D3</td>
<td>1x10^-10</td>
<td>74</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>1x10^-9</td>
<td>925</td>
<td>881</td>
</tr>
<tr>
<td></td>
<td>1x10^-8</td>
<td>1475</td>
<td>1441</td>
</tr>
<tr>
<td>1α,24(S)-(OH)2D2</td>
<td>5x10^-10</td>
<td>425</td>
<td>381</td>
</tr>
<tr>
<td></td>
<td>5x10^-9</td>
<td>1350</td>
<td>1306</td>
</tr>
<tr>
<td></td>
<td>5x10^-8</td>
<td>1182</td>
<td>1138</td>
</tr>
<tr>
<td>1α,24(R)-(OH)2D2</td>
<td>1x10^-9</td>
<td>80</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>1x10^-8</td>
<td>1100</td>
<td>1056</td>
</tr>
<tr>
<td></td>
<td>1x10^-7</td>
<td>1300</td>
<td>1256</td>
</tr>
</tbody>
</table>

*Averages of duplicate determinations

---

**INHIBITION OF CELL PROLIFERATION**

**Example 8:** 1α,24-dihydroxyvitamin D2 [1α,24-(OH)2D2]

Inhibition of cell proliferation is demonstrated using the techniques of Skowronski et al., 132 Endocrinology (1993) 1952-1960 and 136 Endocrinology (1995)
20-26, both of which are incorporated herein by reference. The cell lines, LNCaP and PC-3, which are derived from human prostate adenocarcinoma, are seeded in six-well tissue culture plates at a density of about 50,000 cells/plate. After the cells have attached and stabilized, about 2-3 days, the medium is replenished with medium containing vehicle or the active vitamin D analogue 1α,24-(OH)2D2, at concentrations from 10⁻¹¹ M to 10⁻⁷ M. Medium containing test analogue or vehicle is replaced every three days. After 6-7 days, the medium is removed, the cells are rinsed, precipitated with cold 5% trichloroacetic acid, and washed with cold ethanol. The cells are solubilized with 0.2 N sodium hydroxide, and the amount of DNA determined by standard procedures. The results show that cultures incubated with 1α,24-(OH)2D₂ in accordance with the present invention have significantly fewer cells than the control cultures.

**Example 9:** 1α,24-dihydroxy vitamin D₄ [1α,24-(OH)₂D₄]

The procedure of Example 8 is repeated using the active vitamin D analogue 1α,24-(OH)₂D₄, and the cell number is determined. Cultures incubated with 1α,24-(OH)₂D₄ have significantly fewer cells than the control cultures.

**Example 10:** 1α,25-dihydroxyvitamin D₄ [1α,25-(OH)₂D₄]

The procedure of Example 8 is repeated using the active vitamin D analogue 1α,25-(OH)₂D₄, and the cell number is determined. Cultures incubated with 1α,25-(OH)₂D₄ have significantly fewer cells than the control cultures.

**STIMULATION OF CELL DIFFERENTIATION**

**Example 11:** 1α,24-dihydroxyvitamin D₂ [1α,24-(OH)₂D₂]

Using the techniques of Skowronska et al., 132 *Endocrinology* (1993) 1952-1960 and 136 *Endocrinology* (1995) 20-26, both of which are incorporated herein by reference, cells of the cell line, LNCaP, which is derived from a human metastatic prostate adenocarcinoma and known to express PSA, are seeded in six-well tissue culture plates at a density of about 50,000 cells/plate. After the cells have attached and
stabilized, about 2-3 days, the medium is replenished with medium containing vehicle or the active vitamin D analogue, 1α,24-(OH)2D3, at concentrations from 10^-11 M to 10^-7 M. After 6-7 days, the medium is removed and stored at -20EC for prostate specific antigen (PSA) analysis.

The cells from parallel cultures are rinsed, precipitated, and the amount of DNA determined by standard procedures. PSA is measured by standard known methods. Cultures incubated with 1α,24-(OH)2D2 have significantly more PSA than control cultures when expressed as mass of PSA/cell.

**Example 12:** 1α,24-dihydroxyvitamin D₄ [1α,24-(OH)₂D₄]

The procedure of Example 12 is repeated except the active vitamin D analogue is 1α,24-(OH)₂D₄. The PSA is measured and cultures incubated with 1α,24-(OH)₂D₄ have significantly more PSA than control cultures when expressed as mass of PSA/cell.

**Example 13:** 1α,25-dihydroxyvitamin D₄ [1α,24-(OH)₂D₄]

The procedure of Example 12 is repeated except the active vitamin D analogue is 1α,25-(OH)₂D₄. The PSA is measured and cultures incubated with 1α,25-(OH)₂D₄ have significantly more PSA than control cultures when expressed as mass of PSA/cell.

**CLINICAL STUDIES**

**Example 14:** General Treatment of MAH

Patients with malignancy-associated hypercalcemia participate in an open-label study of a hypocalcemic vitamin D compound in accordance with the present invention. Patients are restricted to daily calcium intake of about 400-500 mg. Each patient is also asked to drink 4-6 cups of fluid more than usual intake to assure adequate oral hydration.

Each subject is monitored at regular intervals for: (1) hypercalcemia, serum PTHrP levels, hyperphosphatemia, hypercalciuria, hyperphosphaturia and other toxicity; (2) evidence of changes in the progression of metastatic disease; and (3) compliance with the prescribed test drug dosage.
The dosing regimen is typically on a daily dose basis of 10 µg or 20 µg per day to about 100 µg/day for 10 weeks. Alternatively, a non-daily dosing regimen can be used, e.g., 40 µg given every other day, 100 µg given once a week. The route of administration can vary from oral to intravenous to regional delivery (e.g., arterial infusion, via the portal vein). Oral is, of course, the easiest and most cost effective route. Regional delivery permits high dosing and generally avoids any production of hypercalcemia. Although, in the case of the compound of the present invention, the compound is substantially hypocalcemic.

After the treatment period, CAT, scans, X-rays and bone scans used for evaluating the progress of metastatic disease show stable disease or partial remission in many patients treated at the lower dosage, and stable disease and partial or complete remission in many patients treated at the higher dosage. Serum calcium levels are in the normal range and serum levels of PTHrP are reduced.

**Example 15:** Treatment of MAH using 1α,24(s)-dihydroxyvitamin D₂ [1α,24(S)-\((\text{OH})_2\text{D}_2\)]

The procedure of example 14 is carried out using 1α,24-(OH)₂D₂. The results show serum calcium levels in the normal range and serum levels of PTHrP reduced.

**Example 16:** Treatment of MAH using 1α-hydroxyvitamin D₂ [1α-OH-D₂]

The procedure of example 14 is carried out using 1α-OH-D₂. The results show serum calcium in the normal range and serum PTHrP levels reduced.

While the present invention has now been described and exemplified with some specificity, those skilled in the art will appreciate the various modifications, including variations, additions, and omissions, that may be made in what has been described. Accordingly, it is intended that these modifications also be encompassed by the present invention and that the scope of the present invention be limited solely by the broadest interpretation lawfully accorded the appended claims.
What is claimed is:

1. A method of treating hypercalcemia associated with malignant or neoplastic cells, comprising treating the cells with an effective amount of a hypocalcemic vitamin D compound having a hydrocarbon moiety at the C24 position.

2. The method of claim 1, wherein the cells are cancers of the breast, colon, lung, neck and head, pancreas, endometrium, bladder, cervix, testes, ovaries, squamous cell carcinoma, myeloid and lymphocytic leukemia, lymphoma, medullary thyroid carcinoma, melanoma, multiple myeloma, retinoblastoma or sarcomas of the soft tissues and bone.

3. The method of claim 1, wherein the hypocalcemic vitamin D is a compound represented by formula (I)

![Chemical Structure](image)

wherein A1 and A2 each are hydrogen or a carbon-carbon bond, thus forming a double bond between C-22 and C-23; R1 and R2 are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that R1 and R2 cannot both be an alkenyl group, or taken together with the carbon to which they are bonded, form a C3-C8 cyclocarbon ring; R3 is lower alkyl,
lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; X\(^1\) is hydrogen or hydroxyl, or, taken with R\(^3\), constitutes a bond when R\(^3\) is an alkenyl group, and X\(^2\) is hydrogen or hydroxyl, or, taken with R\(^1\) or R\(^2\), constitutes a double bond, and X\(^3\) is hydrogen or hydroxyl provided that at least one of X\(^1\), X\(^2\) and X\(^3\) is hydroxyl; and Y is a methylene group if the bond to Y is a double bond or is a methyl group or hydrogen if the bond to Y is a single bond.

4. The method of claim 1, wherein said hypocalcemic vitamin D is a 1\(\alpha\)-hydroxvitamin D compound is represented by formula (I)

\[
\begin{align*}
\text{wherein } A^1 \text{ and } A^2 \text{ each are hydrogen or a carbon-carbon bond, thus forming a double} \\
\text{bond between C-22 and C-23; } R^1 \text{ and } R^2 \text{ are identical or different and are hydrogen,} \\
\text{hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower} \\
\text{fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with} \\
\text{the proviso that } R^1 \text{ and } R^2 \text{ cannot both be an alkenyl group, or taken together with the} \\
\text{carbon to which they are bonded, form a C}_3\text{-C}_8 \text{ cyclocarbon ring; } R^3 \text{ is lower alkyl,} \\
\text{lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl,} \\
\text{O-lower acyl, O-aromatic acyl or lower cycloalkyl; } X^1 \text{ is hydrogen or hydroxyl, or,} \\
\text{taken with } R^3, \text{ constitutes a bond when } R^3 \text{ is an alkenyl group, and } X^2 \text{ is hydrogen or} \\
\text{hydroxyl, or, taken with } R^1 \text{ or } R^2, \text{ constitutes a double bond.}
\end{align*}
\]
5. The method of claim 4, wherein the compound of formula (I) is 1α,24-dihydroxyvitamin D₂, 1α,24-dihydroxyvitamin D₃, 1α,25-dihydroxyvitamin D₂, 1α,25-dihydroxyvitamin D₃, 1α-hydroxyvitamin D₂ or 1α-hydroxyvitamin D₃.

6. A method in accordance with claim 1, wherein a dosing regimen for the hypocalcemic vitamin D compound is a daily regimen or an episodic regimen.

7. A method in accordance with claim 6, wherein the episodic regimen is a dose once every 2 to 7 days.

8. A method in accordance with claim 6, wherein the hypocalcemic vitamin D compound is administered daily at a dose of about 10 to 100 µg/day.

9. A method in accordance with claim 6, wherein the hypocalcemic vitamin D compound is orally, intravenously or regionally delivered to a cancer site.

10. A method in accordance with claim 9, wherein the hypocalcemic vitamin D compound is administered orally.

11. A method in accordance with claim 1, wherein the hypocalcemic vitamin D compound is co-administered with a cytotoxic agent.

12. A method in accordance with claim 11, wherein the cytotoxic agent is an antimetabolite, and antimicrotubule agent, an alkylating agent, a platinum agent, an anthracycline, a topoisomerase inhibitor, or an antibiotic.

13. A method in accordance with claim 12, wherein the antimetabolite is 5-fluoro-uracil, methotrexate or fludarabine.

14. A method in accordance with claim 12, wherein the antimicrotubule agent is vincristine, vinblastine or a taxane.

15. A method in accordance with claim 14, wherein the taxane is paclitaxel or docetaxel.

16. A method in accordance with claim 12, wherein the alkylating agent is cyclophosphamide, melphalan, biochboroethylnitrosurea or hydroxyurea.
17. A method in accordance with claim 12, wherein the platinum agent is cisplatin, carboplatin, oxaliplatin, JM-216 or CI-973.

18. A method in accordance with claim 12, wherein the anthracycline is doxorubicin or daunorubicin.

19. A method in accordance with claim 12, wherein the antibiotic is mitomycin, idarubicin, adriamycin or daunomycin.

20. A method in accordance with claim 12, wherein the topoisomerase inhibitor is etoposide or camptothecins.

21. A method in accordance with claim 12 wherein the cytotoxic agent is estramustine phosphate or prednimustine.

22. A method of treating a human to alleviate hypercalcemia associated with breast cancer, colon cancer, prostate cancer, testicular cancer, pancreatic cancer, endometrial cancer, small cell and non-small cell cancer of the lung (including squamous, adenocarcinoma and large cell types), squamous cell of the head and neck, bladder, ovarian and cervical cancers, myeloid and lymphocytic leukemia, lymphoma, hepatic tumors, medullary thyroid carcinoma, multiple myeloma, melanoma, retinoblastoma or sarcomas of the soft tissue and bone, comprising administering to the human therapeutic amount of a hypocalcemic vitamin D compound.

23. A method of claim 22, wherein said hypocalcemic vitamin D is a 1α-hydroxyvitamin D compound represented by formula (III).
wherein A\(^1\) and A\(^2\) each are hydrogen or a carbon-carbon bond, thus forming a double bond between C-22 and C-23; R\(^1\) and R\(^2\) are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that R\(^1\) and R\(^2\) cannot both be an alkenyl group, or taken together with the carbon to which they are bonded, form a C\(_3\)-C\(_8\) cyclocarbon ring; R\(^3\) is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; X\(^1\) is hydrogen or hydroxyl, or, taken with R\(^3\), constitutes a bond when R\(^3\) is an alkenyl group, and X\(^2\) is hydrogen or hydroxyl, or, taken with R\(^1\) or R\(^2\), constitutes a double bond.

24. The method of claim 23, wherein said therapeutic amount is 0.01 µg/kg/day to 2.0 µg/kg/day.

25. The method of claim 23, wherein the compound of formula (I) is 1α,24-dihydroxyvitamin D\(_2\), 1α,24-dihydroxyvitamin D\(_4\), 1α,25-dihydroxyvitamin D\(_2\), 1α,25-dihydroxyvitamin D\(_4\), 1α-hydroxyvitamin D\(_2\) or 1α-hydroxyvitamin D\(_4\).

26. A method of treating a human to alleviate hypercalcemia associated with malignant cells, comprising administering to the patient a hypocalcemic vitamin D compound, and a cytotoxic agent.
27. A method in accordance with claim 26, wherein the hypocalcemic vitamin D compound is administered from 0.5 to 7 days prior to administration of the cytotoxic agent.

28. A method in accordance with claim 26, wherein the hypocalcemic vitamin D compound is administered 2 to 4 days prior to administration of the cytotoxic agent.
29. A method of claim 26, wherein said hypocalcemic vitamin D is a 1α-hydroxyvitamin D compound represented by formula (III)

\[
\begin{align*}
\text{H} & \\
\text{HO} & \\
\text{OH} & \\
\end{align*}
\]

wherein \( A^1 \) and \( A^2 \) each are hydrogen or a carbon-carbon bond, thus forming a double bond between C-22 and C-23; \( R^1 \) and \( R^2 \) are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that \( R^1 \) and \( R^2 \) cannot both be an alkenyl group, or taken together with the carbon to which they are bonded, form a C\_3-C\_8 cyclocarbon ring; \( R^3 \) is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl; \( X^1 \) is hydrogen or hydroxyl, or, taken with \( R^3 \), constitutes a bond when \( R^3 \) is an alkenyl group, and \( X^2 \) is hydrogen or hydroxyl, or, taken with \( R^1 \) or \( R^2 \), constitutes a double bond.

30. The method of claim 29, wherein the therapeutic amount is 0.01 \( \mu \)g/kg/day to 2.0 \( \mu \)g/kg/day.

31. The method of claim 29, wherein the compound of formula (I) is 1α,24-dihydroxyvitamin D\_2, 1α,24-dihydroxyvitamin D\_3, 1α,25-dihydroxyvitamin D\_2, 1α,25-dihydroxyvitamin D\_4, 1α-hydroxyvitamin D\_2 or 1α-hydroxyvitamin D\_4.
32. A method in accordance with claim 29, wherein the cytotoxic agent is an antimitabolite, and antimicrotubule agent, an alkylating agent, a platinum agent, an anthracycline, a topoisomerase inhibitor, or an antibiotic.

33. A method of lowering serum parathyroid hormone related protein in a human patient by administering to the human an effective amount of a hypocalcemic vitamin D compound.